Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Wave Life Sciences (WVE) EBIAT (2016 - 2026)

Wave Life Sciences (WVE) has disclosed EBIAT for 12 consecutive years, with -$26.1 million as the latest value for Q1 2026.

  • For Q1 2026, EBIAT rose 44.35% year-over-year to -$26.1 million; the TTM value through Mar 2026 reached -$183.6 million, down 63.44%, while the annual FY2025 figure was -$204.4 million, 110.68% down from the prior year.
  • EBIAT hit -$26.1 million in Q1 2026 for Wave Life Sciences, up from -$53.2 million in the prior quarter.
  • Across five years, EBIAT topped out at $29.3 million in Q4 2024 and bottomed at -$61.8 million in Q3 2024.
  • Average EBIAT over 5 years is -$32.2 million, with a median of -$37.8 million recorded in 2022.
  • On a YoY basis, EBIAT climbed as much as 279.95% in 2024 and fell as far as 951.9% in 2024.
  • Wave Life Sciences' EBIAT stood at -$43.7 million in 2022, then surged by 62.81% to -$16.3 million in 2023, then soared by 279.95% to $29.3 million in 2024, then plummeted by 281.79% to -$53.2 million in 2025, then surged by 50.94% to -$26.1 million in 2026.
  • According to Business Quant data, EBIAT over the past three periods came in at -$26.1 million, -$53.2 million, and -$53.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.